Biphasic calcium phosphate ceramics for bone reconstruction: A review of biological response.
Autologous bone graft is considered as the gold standard in bone reconstructive surgery. However, the quantity of bone available is limited and the harvesting procedure requires a second surgical site resulting in severe complications. Due to these limits, scientists and clinicians have considered alternatives to autologous bone graft. Calcium phosphates (CaPs) biomaterials including biphasic calcium phosphate (BCP) ceramics have proven efficacy in numerous clinical indications. Their specific physico-chemical properties (HA/TCP ratio, dual porosity and subsequent interconnected architecture) control (regulate/condition) the progressive resorption and the bone substitution process. By describing the most significant biological responses reported in the last 30years, we review the main events that made their clinical success. We also discuss about their exciting future applications as osteoconductive scaffold for delivering various bioactive molecules or bone cells in bone tissue engineering and regenerative medicine.



Nowadays, BCPs are definitely considered as the gold standard of bone substitutes in bone reconstructive surgery. Among the numerous clinical studies in literature demonstrating the performance of BCP, Passuti et al. and Randsford et al. studies largely contributed to the emergence of the BCPs. It could be interesting to come back to the main events that made their success and could explain their large adhesion from scientists to clinicians. This paper aims to review the most significant biological responses reported in the last 30years, of these BCP-based materials. We also discuss about their exciting future applications as osteoconductive scaffold for delivering various bioactive molecules or bone cells in bone tissue engineering and regenerative medicine.
Université de Nantes, CNRS, UMR 6230, CEISAM, 2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France.
J M
JM
Bouler
Université de Nantes, INSERM, UMR 1229, RMeS, BP 84215, 44042 Nantes Cedex 1, France.
P
P
Pilet
Université de Nantes, INSERM, UMR 1229, RMeS, BP 84215, 44042 Nantes Cedex 1, France; Center for Research and Preclinical Investigation, ONIRIS Nantes-Atlantic College of Veterinary Medicine, Food Science and Engineering, Nantes, France.
O
O
Gauthier
Université de Nantes, INSERM, UMR 1229, RMeS, BP 84215, 44042 Nantes Cedex 1, France. Electronic address: elise.verron@univ-nantes.fr.
E
E
Verron
D000818:Animals; D001861:Bone Regeneration; D018786:Bone Substitutes / Q000737:chemistry*; D016025:Bone Transplantation; D002516:Ceramics / Q000737:chemistry*; D016503:Drug Delivery Systems; D006801:Humans; D006882:Hydroxyapatites / Q000737:chemistry*; D008422:Materials Testing; D016348:Osseointegration; D016062:Porosity; D044968:Regenerative Medicine; D023822:Tissue Engineering; D054457:Tissue Scaffolds / Q000737:chemistry
D018786:Bone Substitutes; D006882:Hydroxyapatites; C074950:hydroxyapatite-beta tricalcium phosphate
BCP; Bone biomaterial; Bone regeneration; In vitro; In vivo; Osteoconduction; Osteoinduction; Porosity